CRISPR/Cas system as a novel therapeutic strategy to combat multi-drug-resistant bacteria.

Zubair A, Hemal MAKP, Ahmed A, Ahmad F, Waheed Y, Afghan N.

DOI: 10.1007/s00203-026-05118-8
Published: 2026-08-05
Container: Arch Microbiol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00203-026-05118-8,
  title = {CRISPR/Cas system as a novel therapeutic strategy to combat multi-drug-resistant bacteria.},
  author = {Zubair A and  Hemal MAKP and  Ahmed A and  Ahmad F and  Waheed Y and  Afghan N.},
  year = {2026},
  journal = {Arch Microbiol},
  doi = {10.1007/s00203-026-05118-8},
  url = {https://doi.org/10.1007/s00203-026-05118-8}
}

RIS

TY  - JOUR
TI  - CRISPR/Cas system as a novel therapeutic strategy to combat multi-drug-resistant bacteria.
AU  - Zubair A
AU  -  Hemal MAKP
AU  -  Ahmed A
AU  -  Ahmad F
AU  -  Waheed Y
AU  -  Afghan N.
PY  - 2026
JO  - Arch Microbiol
DO  - 10.1007/s00203-026-05118-8
UR  - https://doi.org/10.1007/s00203-026-05118-8
ER  -

APA

A, Z., MAKP, H., A, A., F, A., Y, W., & N., A. (2026). CRISPR/Cas system as a novel therapeutic strategy to combat multi-drug-resistant bacteria.. Arch Microbiol. https://doi.org/10.1007/s00203-026-05118-8

Source records

europe-pmc · retrieved 2026-09-27T05:59:58.128Z